Maxicortan Maxicortan


Maxicortan is a drug with a double dose of the active substance* that is well known and used locally for inflammations of the skin, and in indications such as atopic dermatitis, allergic contact eczema, urticaria as well as reactions that occur after insect stings or bites (like itching and irritation).

Maxicortan contains a maximum dose of hydrocortisone (10 mg/g)**, now available without a prescription. Maxicortan cream, when applied locally, indicates anti-inflammatory, antipruritic and vasoconstrictive effects.

*1g of Maxicortan cream contains 10mg of hydrocortisone acetate, i.e. a double dose of the active substance in comparison with creams containing 1mg of 5mg of hydrocortisone acetate.

** Refers to Hydrocortisoni acetas cream available on the Polish market.

Pharmaceutical form Creme. 10 mg/g - 15 g

Category OTC

Additional information

Dosage and administration:

Dosage: apply a small amount of cream to the affected area 1 or 2 times a day. The medicinal product should not be used on large areas of the skin. Do not use for more than 7 days.
Children: Maxicortan is not intended for use in children below 12 years of age. Method of administration: topical application to the skin.

Active substance

Active substance: 1 g of the cream contains 10 mg of hydrocortisone acetate (Hydrocortisoni acetas). Excipients with known effect: cetyl alcohol, stearyl alcohol, propylene glycol, methyl parahydroxybenzoate, propyl parahydroxybenzoate.


Maxicortan is used topically for inflammations of the skin of various origins, primarily allergic, of medium severity, which respond to glucocorticosteroids. The medicinal product is used topically for the following indications: atopic dermatitis; allergic contact eczema, urticaria; reactions that occur after insect stings or bites (such as itching and irritation).


Hypersensitivity towards hydrocortisone acetate or to any of the excipients, bacterial, viral or fungal infections; acne vulgaris; rosacea; skin atrophy; skin cancers and precancerous conditions; dermatitis perioralis; tuberculosis lesions of the skin; open wounds and damaged skin; concomitant systemic mycosis; facial skin; children under 12 years of age.

Marketing Authorisation Holder

Aflofarm Farmacja Polska Spółka z o.o.

Marketing Authorisation


Information for the patient

Read the package leaflet for indications, contraindications, side effects, dosage as well as information on the use of this product, or consult your doctor or pharmacist before use. Misusing medicines may be dangerous to your life or health.

See how we care about quality

All our products are subject to strict safety requirements

We use rigorous quality control standards and procedures to ensure the highest level of safety for all our products.

See how we care about safety